Akcea Therapeutics (AKCA) Misses Q4 EPS by 14c

Akcea Therapeutics (NASDAQ: AKCA) reported Q4 EPS of ($0.35), $0.14 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $18 million, versus $31 million reported last year.

For earnings history and earnings-related data on Akcea Therapeutics (AKCA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c